European Primary Care Cardiovascular Society

Lipid-lowering drug prescription decreases with age but increases with frailty

Prescription patterns of lipid lowering agents among older patients in general practice: an analysis from a national database in the Netherlands

Literature - Kleipool EEF, Nielen MMJ, Korevaar JC et al. - Age and Ageing 2019; doi: 10.1093/ageing/afz034

Introduction and methods

According to Dutch guidelines, lipid-lowering drugs (LLDs) are recommended for patients with prior CVD because of their (very) high CV risk [1]. In subjects without CVD, every male and almost every female ≥70 years of age without CVD is eligible for LLDs to prevent CVD-related morbidity and mortality, solely based on their age, according to a risk stratification tool that estimates 10-years risk of a CV event or mortality [2].

There are only little data on prescription patterns of LLDs in older people in relation with age, frailty and comorbidities. Particularly older and frail adults with a shorter life expectancy may receive preventive drugs less often, because they may be less likely to benefit from LLDs and more likely to be harmed [3]. A previous study has shown reduced statin treatment in older patients with and without pre-existing CVD and high comorbidity-scores, compared to those with fewer comorbidities [4]. Also, risk of institutionalization and mortality was not reduced with statin therapy in frail older men ≥70 years of age [5].

This study (n=224.328) assessed how many people ≥70 years, with (n=55.309) and without (n=189.019) prior CVD, were prescribed an LLD, according to age, level of frailty, and number of comorbidities, using data from the large Nivel Primary Care Database (NIVEL-PCD) in The Netherlands (2011-2015). LLDs were defined as drugs belonging to the C10 ‘Lipid-modifying agents’ category (e.g. statins and fibrates), in the Anatomical Therapeutic Chemical (ATC) classification system. Vascular and non-vascular comorbidities were recorded using the International Classification of Primary Care-1 (IPCS-1) of the WHO. Atherosclerotic-related CVD at baseline was defined as: angina pectoris, acute MI, MI >4 weeks ago, TIA, stroke, or peripheral artery disease. Prevalence of LLD use was examined according to age (70-74, 75-80, 81-84, 85-90 and ≥91 years of age), frailty (tertiles based on the Drubbel-frailty index), number of chronic disease at baseline (0-3, 4-8, ≥9) and number of primary care visits during the first year after baseline (0-3, 4-8, ≥9).

Main results

LLD use according to age

LLD use according to age and frailty

LLD use according to age, comorbidities and primary care visits

Conclusion

An analysis of a large Dutch primary care database showed that general practitioners are less likely to prescribe LLD treatment with increasing age in subjects ≥70 years. Contrary to expectations, LLD use was seen more often in frail older adults compared to non-frail older adults. In this group, the benefits may, however, not outweigh the harms of LLD. Thus, competing risks, time-to-benefit vs. estimated life expectancy and level of frailty should be taken into account in decision-making on LLDs in older individuals.

References

Show references

Find this article online at Age and Ageing

Share this page with your colleagues and friends: